The FDA approved ensitrelvir (Xocova) for post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older following contact with an individual with COVID-19.
Following three clinical trials, the FDA has approved a new preventive treatment for neonates, infants, and toddlers that prevents respiratory syncytial virus (RSV) in those age populations.
The FDA has approved a treatment option for adults with multidrug resistant HIV infection, marking a “new class of antiretroviral medications” for this patient population.
The US Food and Drug Administration approved a drug for the treatment of HIV-1 infection in conjunction with other antiretroviral therapies among children aged at least 4 weeks who weigh at least 3 kg.
...
After performance data showed 95% sensitivity and specificity, the FDA authorized the assay’s marketing in the United States for detection of HIV-1 drug-resistant mutations.
After performance data showed 95% sensitivity and specificity, the FDA authorized the assay’s marketing in the United States for detection of HIV-1 drug-resistant mutations.
